Discover
ENTA
Enanta Pharmaceuticals, Inc.
14.77
2 x 10.73
2 x 18.90
bid
ask
+
0.19
1.30%
2 @ 04:00 PM
14.77 +0.00 (0.00%)
| Ytd | -6.34% | |
| 1y | 91.82% |
14.63
day range
15.20
6.43
52 week range
17.15
| Open | 14.63 | Prev Close | 14.58 | Low | 14.63 | High | 15.20 | Mkt Cap | 429.49M |
| Vol | 198.52K | Avg Vol | 199.32K | EPS | -2.60 | P/E | N/A | Forward P/E | -1.32 |
| Beta | 0.57 | Short Ratio | 20.91 | Inst. Own | 100.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 13.36 | 200-d Avg | 12.91 | 1yr Est | 16.88 |
ENTA News
benzinga.com
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy
benzinga.com
Enanta Pharma Advances Zelicapavir Into Registrational Phase 2b/3 Clinical Trial In Adults At High R
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with